tetano
Editor, Senior Moderator
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2020 Oct 28;45(10):1172-1175.
doi: 10.11817/j.issn.1672-7347.2020.200421.
Influential factor and trend of specific IgG antibody titer in coronavirus disease 2019 convalescents
[Article in En, Chinese]
Chenggao Wu[SUP] 1 [/SUP], Wei Liu[SUP] 2 [/SUP], Guoliang Li[SUP] 2 [/SUP], Zhanglin Zhang[SUP] 2 [/SUP], Kun Xiao[SUP] 2 [/SUP], Aiping LE[SUP] 3 [/SUP]
Affiliations
Abstract
in English, Chinese
Objectives: To explore the influential factors and titer trend of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific IgG antibody in convalescent patients with coronavirus disease 2019 (COVID-19), and to provide theoretical basis for the feasibility of clinical treatment of convalescent plasma.
Methods: Colloidal gold immunochromatography assay was used to detect the SARS-CoV-2 specific IgG antibody and its titer in 113 convalescent patients with COVID-19 who were followed up from February 19, 2020 to April 6, 2020. The basic characteristics and treatment factors of patients in the high titer group (antibody titer≥1꞉160, n=22) and the low titer group (antibody titer <1꞉160, n=91) were analyzed. The IgG antibody titer in the high titer group was continuously monitored and the trend of titer was analyzed.
Results: The difference in the clinical type of COVID-19, onset time, first admission C-reactive protein, absolute value of lymphocyte, absolute value of CD19[SUP]+[/SUP]CD3[SUP]-[/SUP] lymphocytes, and the treatment of glucocorticoid were not statistically significant between the patients in the high titer group and the low titer group (all P>0.05). The male patients in the high titer group were more than those in the low titer group (P<0.05). The titer of SARS-CoV-2 specific IgG antibody in the high titer group decreased to less than 1꞉160 28 d after discharge.
Conclusions: Male COVID-19 patients might be more likely to produce high titer SARS-CoV-2 specific IgG antibodies than female. The peak level of SARS-CoV-2 specific IgG antibody in convalescent patients is maintained for a short period. Using plasma from convalescent COVID-19 patients for treatment should be within 28 d after discharge.
Keywords: IgG antibody; antibody titer; convalescent plasma; coronavirus disease 2019.
. 2020 Oct 28;45(10):1172-1175.
doi: 10.11817/j.issn.1672-7347.2020.200421.
Influential factor and trend of specific IgG antibody titer in coronavirus disease 2019 convalescents
[Article in En, Chinese]
Chenggao Wu[SUP] 1 [/SUP], Wei Liu[SUP] 2 [/SUP], Guoliang Li[SUP] 2 [/SUP], Zhanglin Zhang[SUP] 2 [/SUP], Kun Xiao[SUP] 2 [/SUP], Aiping LE[SUP] 3 [/SUP]
Affiliations
- PMID: 33268577
- DOI: 10.11817/j.issn.1672-7347.2020.200421
Abstract
in English, Chinese
Objectives: To explore the influential factors and titer trend of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific IgG antibody in convalescent patients with coronavirus disease 2019 (COVID-19), and to provide theoretical basis for the feasibility of clinical treatment of convalescent plasma.
Methods: Colloidal gold immunochromatography assay was used to detect the SARS-CoV-2 specific IgG antibody and its titer in 113 convalescent patients with COVID-19 who were followed up from February 19, 2020 to April 6, 2020. The basic characteristics and treatment factors of patients in the high titer group (antibody titer≥1꞉160, n=22) and the low titer group (antibody titer <1꞉160, n=91) were analyzed. The IgG antibody titer in the high titer group was continuously monitored and the trend of titer was analyzed.
Results: The difference in the clinical type of COVID-19, onset time, first admission C-reactive protein, absolute value of lymphocyte, absolute value of CD19[SUP]+[/SUP]CD3[SUP]-[/SUP] lymphocytes, and the treatment of glucocorticoid were not statistically significant between the patients in the high titer group and the low titer group (all P>0.05). The male patients in the high titer group were more than those in the low titer group (P<0.05). The titer of SARS-CoV-2 specific IgG antibody in the high titer group decreased to less than 1꞉160 28 d after discharge.
Conclusions: Male COVID-19 patients might be more likely to produce high titer SARS-CoV-2 specific IgG antibodies than female. The peak level of SARS-CoV-2 specific IgG antibody in convalescent patients is maintained for a short period. Using plasma from convalescent COVID-19 patients for treatment should be within 28 d after discharge.
Keywords: IgG antibody; antibody titer; convalescent plasma; coronavirus disease 2019.